Overview

Individualized Response to Vitamin D Treatment Study

Status:
Active, not recruiting

Trial end date:
2021-11-01

Target enrollment:
0

Participant gender:
All

Summary

The goal of this clinical trial is to determine individual-level genetic and metabolic characteristics that modify the response to cholecalciferol treatment. This study is double blind, parallel design, randomized clinical trial that will assess genetic and metabolic characteristics that modify the response to cholecalciferol treatment. . Eligible participants will be randomly assigned to receive cholecalciferol treatment (2,000 international units of cholecalciferol daily by mouth) or placebo in a 3:1 ratio for a total duration of 16-weeks. The planned sample size is 1,600. The primary aim of this study is to identify genetic polymorphisms, clinical characteristics, and biomarkers that modify the biologic response to vitamin D3 treatment, assessed by changes in serum concentrations of parathyroid hormone (PTH) and 1,25(OH)2D and urine calcium excretion.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ian deBoer
University of Washington

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Cholecalciferol
Ergocalciferols
Vitamin D
Vitamins

Criteria

Inclusion Criteria:

1,600 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) study who are
returning for their scheduled 6th MESA study visit.

Participants will be recruited from four field centers: Wake Forest University,
Winston-Salem, NC; Columbia University, New York, NY; Northwestern University, Evanston,
IL; and Johns Hopkins University, Baltimore, MD.

Exclusion Criteria:

1. Current use of >1,000 international units (IU) of cholecalciferol daily

2. Current use of any activated vitamin D product (calcitriol, paricalcitol, hectorol)

3. Known history of allergy or adverse reaction to vitamin D treatment

4. Known clinical history of primary hyperparathyroidism

5. Known clinical history of kidney stones within the previous 5 years

6. Current participation in another interventional study

7. Inability to provide written informed consent